Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.56 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NQO1 | P15559 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311305 | 0.82 | NQO1 (0.48) | MAOBMAOAPTPN1ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL11645615 | 0.80 | NQO1 (0.47) | MAOBMAOAPTPN1ALDH1A1KDM4E | |
| SCHEMBL27755477 | 0.77 | MAOB (0.58) | MAOBMAOAPTPN1ALDH1A1KDM4E | |
| SCHEMBL11394269 | 0.75 | MAOB (0.39) | MAOBMAOAPTPN1ALDH1A1KDM4E | |
| SCHEMBL76091 | 0.75 | MAOB (0.61) | MAOBMAOAPTPN1ALDH1A1KDM4E | |
| SCHEMBL294155 | 0.75 | MAOB (0.56) | MAOBMAOAPTPN1ALDH1A1KDM4E | |
| Methylchromone SCHEMBL29387804 | 0.75 | MAOB (0.56) | MAOBMAOAPTPN1ALDH1A1KDM4E | |
| Methylchromone SCHEMBL25934 | 0.75 | MAOB (0.56) | MAOBMAOAPTPN1ALDH1A1KDM4E | |
| SCHEMBL21936757 | 0.75 | MAOB (0.56) | MAOBMAOAPTPN1ALDH1A1KDM4E | |
| SCHEMBL11740470 | 0.75 | MAOB (0.56) | MAOBMAOAPTPN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| EP-3541812-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | Takeda Pharmaceutical Company Limited (JP) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018092921-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018092921-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-24 | — | — | WO | disclosed |
| CN-1051990-C | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes and 3-aminochromones | LILLY CO ELI (US) | 2000-05-03 | — | — | CN | disclosed |
| CN-1120532-A | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes and 3-aminochromones | LILLY CO ELI (US) | 1996-04-17 | — | — | CN | disclosed |
| EP-0003360-B1 | AZATHIANAPHTHALENE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR UTILISATION | CIBA-GEIGY AG (CH) | 1981-12-30 | — | — | EP | disclosed |
| US-4288450-A | ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1981-09-08 | — | — | US | disclosed |
| US-4259506-A | SELECTIVELY DESTROYING WEEDS IN CROPS | PHILAGRO (FR) | 1981-03-31 | — | — | US | disclosed |
| US-4216155-A | 3-GLYCOLOYLAMINO-4-OXO-4H-1-BENZOPYRAN; ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1980-08-05 | — | — | US | disclosed |
| US-4213980-A | ANTIINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-07-22 | — | — | US | disclosed |
| EP-0003360-A1 | Azathianaphthalene derivatives, process for their preparation, pharmaceutical preparations containing them and their utilisation | CIBA-GEIGY AG (CH) | 1979-08-08 | — | — | EP | disclosed |
| EP-0000488-A1 | 3-Oxaloamino-4-oxo-4H-1-benzopyrane compounds, process for their preparation and their pharmaceutical use | CIBA-GEIGY AG (CH) | 1979-02-07 | — | — | EP | disclosed |
| US-4076729-A | (4-Oxo-4H-1-benzopyran-3-yl)aminooxoacetic acids and their derivatives | WARNER-LAMBERT COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4066655-A | 4,10-Dihydro-4,10-dioxo-1H-1-benzopyrano[3,2-b]pyridine-3-carboxylic acids, salts and esters | WARNER-LAMBERT COMPANY (US) | 1978-01-03 | — | — | US | disclosed |
| US-4046769-A | 4,10-Dihydro-4,10-dioxo-1H-1-benzopyrano[3,2-b]pyridine-2-carboxylic acids and esters | WARNER-LAMBERT COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | GRM7, GRM2, GRM1 | MAOB 2482/4885MAOA 3153/4885PTPN1 1134/4885 |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | GRM7, GRM2, GRM1 | MAOB 2482/4885MAOA 3153/4885PTPN1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.